Detecting Circulating Melanoma Cells

Circulating Melanoma Cells

Circulating melanoma cells and survival in metastatic melanoma.

A validated assay for the enumeration of circulating melanoma cells (CMCs) may facilitate the development of more effective therapies for metastatic melanoma patients. In this study CD146+ cells were immunomagnetically enriched from 7.5 ml of blood. Isolated cells were fluorescently stained with DAPI, anti-molecular weight melanoma-associated antigen (HMW-MAA), anti-CD45 and CD34 and Ki67. CMCs...

Circulating Melanoma Cells: Scoping the Target

CirCulating MelanoMa Cells Molecular markers have been increasingly applied in cancer to assess metastatic risk and to guide treatment, including in melanoma, where assessment of BRAF mutations in tumor tissues to determine suitability for treatment with vemurafenib is now routine (1). Static assessment of tumor tissues, however, does not indicate whether tumor cells are being shed or whether t...

Circulating Tumor Cells in Melanoma Patients

Circulating tumor cells (CTCs) are of recognized importance for diagnosis and prognosis of cancer patients. With melanoma, most studies do not show any clear relationship between CTC levels and stage of disease. Here, CTCs were enriched (∼400X) from blood of melanoma patients using a simple centrifugation device (OncoQuick), and 4 melanocyte target RNAs (TYR, MLANA, MITF, and MIF) were quantifi...

Detecting Circulating Tumor Cells: Current Challenges and New Trends

Circulating tumor cells (CTCs) in the blood stream play a critical role in establishing metastases. The clinical value of CTCs as a biomarker for early cancer detection, diagnosis, prognosis, prediction, stratification, and pharmacodynamics have been widely explored in recent years. However, the clinical utility of current CTC tests is limited mainly due to methodological constraints. In this r...